Status epilepticus in the elderly

Leppik, Ilo E.

doi:10.1111/epi.14497

Cited by 34 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alcohol- and stroke-related cases of SE were less common in our study than in an article by Leppik (19). He found stroke to have caused 52.3% of the cases of SE among the elderly adults and 17.7% in middle-aged adults, while, in our study, the figures were 16.3 and 7.4%, respectively.…”

Section: Discussioncontrasting

confidence: 73%

The Outcome of Status Epilepticus and Long-Term Follow-Up

et al. 2019

View full text Add to dashboard Cite

Objective: This study was to investigate the outcome of status epilepticus (SE) associated with antiepileptic therapy during SE and in follow-up period, risk factors including age, co-morbidities, pre-existing epilepsy, and etiology in the East-Hungarian region. Methods: A prospective cross-sectional database was compiled from outpatient files between 2013 and 2017. Follow-up ended on 30.06.2018. Results: One hundred and thirty five episodes (male: 68, 50.4%) were evaluated, mean age and follow-up time being 64.1 ± 13.9 years and 39.9 ± 14.2 months, respectively. Of the 89 patients with pre-existing epilepsy, 34 failed to visit the outpatient unit regularly. Case fatality rate was 25.2% and 31 patients (30.7%) died after discharge due to co-morbidities; their mean survival time was 10.44 ± 8 months. Focal, generalized and combined type epilepsies were diagnosed in 67 patients (49.6%), 47 patients (34.8%), and 21 patients (15.6%) of SE, respectively. Nine patients had non-convulsive SE (NCSE). Mean seizure-free period was 6.8 ± 6.9 months. Patients taking carbamazepine (20.9%; OR: 0.37, 95%CI: 0.16–0.82; p = 0.018), levetiracetam (27.5%; OR: 0.51, 95%CI: 0.27–0.97; p = 0.041), or valproate (11.1%; OR: 0.18, 95%CI: 0.05–0.61; p = 0.0043) were expected to achieve seizure freedom after SE. The worst outcome was linked to advanced age, etiology, new onset status epilepticus, NCSE, and focal status epilepsy. Conclusion: This study highlights the importance of regular care and patient follow-up.

show abstract

Section: Discussioncontrasting

confidence: 73%

The Outcome of Status Epilepticus and Long-Term Follow-Up

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The mean annual incidence of SE in the elderly ranges between 15.5/100,000 and 25.9/100,000 ( 42 ), with the most common cause being acute symptomatic seizures related to vascular events or brain hypoxia ( 42 ). We found that 4% of elderly patients with new onset seizures presented in status epilepticus, with an epileptogenic lesion detected in all of those patients.…”

Section: Discussionmentioning

confidence: 99%

Frequency and Stratification of Epileptogenic Lesions in Elderly With New Onset Seizures

et al. 2018

View full text Add to dashboard Cite

Objective: To evaluate prospectively the frequency of epileptogenic lesions in a consecutive cohort of elderly patients presenting with new onset unprovoked seizures, and who underwent a complete evaluation including dedicated epilepsy protocol MRI.Methods and materials: We included all consecutive patients 60 years or older who participated in a prospective study on new onset epilepsy. The work-up included the acquisition of a dedicated epilepsy protocol MRI and a 3 h video/EEG recording. We evaluated the frequency and types of epileptogenic lesions in the whole cohort and stratified those variables by age, gender, types and number of seizures at presentation. We also correlated the EEG findings with the clinical characteristics and neuroimaging results.Results: Of the 101 patients enrolled in the study and who underwent an epilepsy protocol MRI, an epileptogenic lesion was identified in 67% of cases. The most common etiologies were vascular events, followed by tumoral causes and traumatic brain injuries. Epileptogenic lesions were more likely to be identified in patients who presented with only focal aware and impaired awareness seizures. In addition, patients with tumoral epilepsy were significantly more likely to only experience those seizure types compared to patients with other pathological substrates. Interictal/ictal discharges were detected in the EEG of 21% of patients. Epileptiform discharges were significantly more frequent in patients with an epileptogenic lesion on brain MRI, especially in those with a brain tumor.Conclusions: Our results stress the importance of obtaining a dedicated epilepsy protocol MRI in elderly patients with new onset seizures. An epileptogenic lesion will be identified in approximately two thirds of patients with important implications regarding initiation of treatment. In addition, the data underscore the value of distinguishing the types of seizures experienced at presentation as this will apprise the treating physician on the likelihood of identifying an epileptogenic lesion and on the probable etiologies.

show abstract

“…24 The mortality rate associated with SE varies with age, and is approximately 50% among individuals aged >80 years. 25…”

Section: Diagnosis: Different Clinical Manifestations In Elderly Patimentioning

confidence: 99%

Pharmacological Treatment of Epilepsy in Elderly Patients

et al. 2020

View full text Add to dashboard Cite

The incidence and prevalence of epilepsy are highest in elderly people, and the etiologies of epilepsy in the elderly differ from those in other age groups. Moreover, diagnosing and treating epilepsy in elderly people may be challenging due to differences in clinical characteristics and physiological changes associated with aging. This review focuses on the pharmacological treatment of epilepsy in elderly patients.

show abstract

Status epilepticus in the elderly

Cited by 34 publications

References 17 publications

The Outcome of Status Epilepticus and Long-Term Follow-Up

The Outcome of Status Epilepticus and Long-Term Follow-Up

Frequency and Stratification of Epileptogenic Lesions in Elderly With New Onset Seizures

Pharmacological Treatment of Epilepsy in Elderly Patients

Contact Info

Product

Resources

About